12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga · 6h ago
Gainers
- Vor Biopharma (NASDAQ:VOR) shares moved upwards by 105.6% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $69.2 million.
- Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 56.95% to $0.39. The market value of their outstanding shares is at $3.8 million.
- Plus Therapeutics (NASDAQ:PSTV) shares increased by 27.42% to $0.4. The company's market cap stands at $16.0 million.
- Kewaunee Scientific (NASDAQ:KEQU) stock increased by 24.5% to $50.4. The company's market cap stands at $115.5 million. As per the news, the Q4 earnings report came out yesterday.
- Passage Bio (NASDAQ:PASG) shares rose 13.46% to $0.37. The company's market cap stands at $20.2 million.
- Aspire Biopharma Hldgs (NASDAQ:ASBP) shares rose 13.23% to $0.27. The company's market cap stands at $11.8 million.
Losers
- Altimmune (NASDAQ:ALT) stock declined by 62.6% to $2.88 during Thursday's pre-market session. The market value of their outstanding shares is at $625.3 million.
- Reviva Pharmaceuticals (NASDAQ:RVPH) stock declined by 31.9% to $0.52. The market value of their outstanding shares is at $35.6 million.
- Crescent Biopharma (NASDAQ:CBIO) shares decreased by 15.56% to $15.2. The company's market cap stands at $351.0 million.
- GlucoTrack (NASDAQ:GCTK) shares fell 14.8% to $6.68. The company's market cap stands at $4.4 million.
- Co-Diagnostics (NASDAQ:CODX) stock fell 11.26% to $0.25. The company's market cap stands at $9.3 million.
- Trinity Biotech (NASDAQ:TRIB) shares declined by 10.43% to $0.67. The company's market cap stands at $14.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.